The Endocrine Society’s Bone and Mineral Special Interest Group (SIG) Steering Committee has issued a call to action for the global medical community to address the persistent diagnostic gap surrounding hypophosphatasia (HPP), a rare and often debilitating inherited metabolic disorder. Ahead of World HPP Day on October 30, 2026, the committee has organized a specialized webinar scheduled for October 29 to equip clinicians with the tools necessary to identify this frequently overlooked condition. Led by Dr. Anika Anam of the Yale School of Medicine and Dr. Azarmindokht Khosravi of Cedars-Sinai, the initiative highlights a critical clinical oversight: the failure to recognize persistently low levels of alkaline phosphatase (ALP) as a primary indicator of HPP. While high ALP levels are routinely investigated for liver or bone pathology, low levels are often dismissed as clinically insignificant, leaving patients at risk of improper treatment and progressive systemic damage.
The Biological Mechanics of TNSALP Deficiency
At its core, hypophosphatasia is caused by loss-of-function mutations in the ALPL gene, which is responsible for encoding tissue-nonspecific alkaline phosphatase (TNSALP). This enzyme plays a non-negotiable role in the mineralization of bones and teeth. Under normal physiological conditions, TNSALP breaks down inorganic pyrophosphate into inorganic phosphate. This inorganic phosphate then binds with calcium to form hydroxyapatite crystals, the fundamental building blocks of skeletal structure.
When TNSALP activity is deficient, inorganic pyrophosphate accumulates to pathological levels. Rather than facilitating mineralization, these high concentrations of pyrophosphate act as a potent inhibitor, effectively blocking the formation of hydroxyapatite. This biochemical bottleneck results in a paradoxical state where the body has sufficient calcium, but cannot utilize it to strengthen bone. Consequently, calcium may deposit in ectopic locations, leading to complications such as nephrocalcinosis (calcium deposits in the kidneys) or periarticular calcifications. Furthermore, TNSALP is essential for the activation of vitamin B6 in the brain. Without it, the synthesis of gamma-aminobutyric acid (GABA) is impaired, which can lead to vitamin B6-responsive seizures, particularly in pediatric patients.
A Spectrum of Severity: The Five Classifications of HPP
HPP is not a monolithic condition; it exists on a broad spectrum of clinical severity. The medical community currently recognizes five primary classifications based on the age of onset and the nature of the symptoms:
- Perinatal HPP: The most severe form, often detectable in utero via ultrasound. It is characterized by a near-complete lack of skeletal mineralization and is frequently fatal due to respiratory failure resulting from an underdeveloped rib cage.
- Infantile HPP: Symptoms typically appear within the first six months of life. These patients may experience failure to thrive, rickets-like skeletal deformities, and hypercalcemia.
- Childhood HPP: This form presents with a range of symptoms from premature loss of primary teeth (often before age five) to delayed walking, "bowed" legs, and frequent fractures.
- Adult HPP: Often diagnosed in middle age, this form is characterized by osteomalacia, recurrent stress fractures, and persistent musculoskeletal pain. It is frequently misdiagnosed as more common ailments.
- Odontohypophosphatasia: This is the mildest form, where the only clinical manifestation is dental abnormality, such as the premature loss of teeth with the roots still intact, without the presence of overt skeletal disease.
The Diagnostic Gap and the Risk of Misdiagnosis
The "diagnostic gap" refers to the significant delay between the onset of symptoms and an accurate diagnosis of HPP. Because many symptoms—such as chronic fatigue, joint pain, and muscle weakness—overlap with common conditions, patients are often incorrectly diagnosed with fibromyalgia, osteoarthritis, or chronic fatigue syndrome.
A primary hurdle in the diagnostic process is the interpretation of laboratory results. Routine metabolic panels include ALP, but the reference ranges provided by laboratories are often optimized to detect high levels rather than low ones. Furthermore, ALP levels are naturally higher in children and adolescents due to active bone growth. A "normal" adult ALP level in a ten-year-old could actually signify a profound deficiency.
To bridge this gap, the SIG Steering Committee emphasizes the use of secondary biomarkers. High levels of plasma pyridoxal 5’-phosphate (PLP), the active form of vitamin B6, and elevated urinary phosphoethanolamine (PEA) are strong indicators of HPP. Genetic testing remains the gold standard for confirmation, as over 480 pathogenic variants of the ALPL gene have been identified to date. Recent genomic screenings suggest a carrier frequency of approximately one in 341 individuals, indicating that the condition may be more prevalent than previously estimated.
Chronology of Awareness and Medical Progress
The journey toward understanding and treating HPP has accelerated significantly over the last decade:
- 1948: Dr. John Rathbun first describes "hypophosphatasia" after observing a low ALP level in an infant with rickets.
- 1988: The ALPL gene is first linked to the disorder, opening the door for molecular diagnostics.
- 2015: The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approve Asfotase alfa, the first enzyme replacement therapy specifically for HPP.
- 2020-2025: Increased focus on adult-onset HPP leads to the discovery of high misdiagnosis rates in rheumatology and orthopedic clinics.
- October 2026: The Endocrine Society’s Bone and Mineral SIG launches a global educational campaign, culminating in the World HPP Day webinar to address the diagnostic void.
This timeline reflects a transition from HPP being viewed as a rare pediatric fatality to being recognized as a lifelong metabolic condition that requires multidisciplinary management across all age groups.
Therapeutic Innovations and Management Precautions
The management of HPP requires a nuanced, multidisciplinary approach involving endocrinologists, nephrologists, dentists, and genetic counselors. The introduction of Asfotase alfa, a bone-targeted recombinant TNSALP, has revolutionized the prognosis for the most severe forms of the disease. By replacing the missing enzyme, the treatment improves skeletal mineralization, respiratory function, and muscle strength.
However, pharmacological intervention is not a universal requirement for all patients. In mild adult-onset cases, the decision to start enzyme replacement therapy must be weighed against the burden of treatment, which involves subcutaneous injections multiple times per week.
A critical component of management is knowing what to avoid. The SIG Steering Committee provides several high-stakes precautions for clinicians:
- Avoid Bisphosphonates: These common osteoporosis medications are synthetic analogues of inorganic pyrophosphate. In an HPP patient who already has an excess of pyrophosphate, bisphosphonates can worsen the mineralization defect and increase the risk of atypical femoral fractures.
- Limit Supplementation: High doses of calcium and vitamin D, standard for many bone conditions, can exacerbate hypercalciuria and increase the risk of kidney stones and nephrocalcinosis in HPP patients.
- Monitor Bone Turnover: Since HPP is a low bone turnover state, osteoanabolic agents (which build bone) are generally preferred over antiresorptive agents (which prevent bone breakdown) if pharmaceutical intervention for bone density is required.
Broader Implications and Global Impact
The implications of improving HPP diagnosis extend beyond the individual patient. Because HPP can be inherited in both autosomal dominant and autosomal recessive patterns, a single diagnosis often leads to the identification of affected family members who may have been suffering from "unexplained" bone pain or dental issues for years.
Furthermore, the study of HPP provides vital insights into the broader mechanics of phosphate metabolism and skeletal health. By understanding how the ALPL gene functions, researchers are gaining a better understanding of how the body regulates mineralization, which could have future implications for treating more common bone density disorders.
The upcoming webinar on October 29 serves as a final call for healthcare providers to integrate ALP screening into their diagnostic logic. As the medical community prepares for World HPP Day 2026, the message remains clear: a low alkaline phosphatase level is not a laboratory error or a clinical curiosity—it is a potential window into a rare disease that, when identified, can be managed to significantly improve a patient’s quality of life. The goal of the Endocrine Society and its SIG Steering Committee is to ensure that "low ALP" becomes a reflex trigger for HPP evaluation, effectively closing the diagnostic gap that has persisted for decades.
